Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
3.620
+0.040 (1.12%)
At close: Apr 1, 2026, 4:00 PM EDT
3.610
-0.010 (-0.28%)
After-hours: Apr 1, 2026, 7:59 PM EDT
Rocket Pharmaceuticals Employees
Rocket Pharmaceuticals had 202 employees as of December 31, 2025. The number of employees decreased by 97 or -32.44% compared to the previous year.
Employees
202
Change (1Y)
-97
Growth (1Y)
-32.44%
Revenue / Employee
n/a
Profits / Employee
-$1,104,569
Market Cap
393.02M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 202 | -97 | -32.44% |
| Dec 31, 2024 | 299 | 31 | 11.57% |
| Dec 31, 2023 | 268 | 28 | 11.67% |
| Dec 31, 2022 | 240 | 89 | 58.94% |
| Dec 31, 2021 | 151 | 60 | 65.93% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| Enanta Pharmaceuticals | 120 |
| Neumora Therapeutics | 95 |
| Century Therapeutics | 78 |
| Lineage Cell Therapeutics | 77 |
| Armata Pharmaceuticals | 60 |
| Altimmune | 57 |
| X4 Pharmaceuticals | 45 |
RCKT News
- 5 days ago - Rocket Pharmaceuticals, Inc. (RCKT) Discusses FDA Approval of KRESLADI Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 Transcript - Seeking Alpha
- 5 days ago - Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder - Reuters
- 5 days ago - Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I) - Business Wire
- 26 days ago - Rocket Pharmaceuticals, Inc. (RCKT) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 4 weeks ago - Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress - Business Wire
- 5 weeks ago - Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Rocket Pharmaceuticals, Inc. (RCKT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 3 months ago - Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire